{"entity":{"id":"michael-wang","kind":"person","name":"Michael L. Wang","aka":[],"tldr":"Led the ibrutinib and brexucabtagene autoleucel trials that transformed mantle cell lymphoma treatment.","summary":"Michael Wang was principal investigator of the pivotal trial of ibrutinib in relapsed mantle cell lymphoma, the first BTK inhibitor approval in the disease, and of ZUMA-2, which established brexucabtagene autoleucel CAR-T therapy for relapsed MCL. He led the chemotherapy-free ibrutinib-rituximab WINDOW trials and the SYMPATICO trial of ibrutinib plus venetoclax. He directs the mantle cell lymphoma programme at MD Anderson.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wang%20ML%5BAuthor%5D%20mantle%20cell%20lymphoma"}],"tags":["lymphoma","mantle-cell","car-t"],"related":[],"cancers":["mantle-cell-lymphoma"],"sections":[],"technologies":["car-t","kinase-inhibitors"],"targets":["cd19","bcl2"],"drugs":["venetoclax"],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-zuma-2-brexu-cel-mantle-cell-nejm-2020"],"journals":[],"dependsOn":[],"notes":[],"role":"Puddin Clarke Endowed Professor, Department of Lymphoma and Myeloma, MD Anderson Cancer Center","institutionId":"md-anderson","specialisms":["Mantle cell lymphoma","BTK inhibitors","CAR T-cell therapy","Chemotherapy-free regimens"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wang%20ML%5BAuthor%5D%20mantle%20cell%20lymphoma"}],"papers":[{"title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma (ZUMA-2)","journal":"NEJM","year":2020,"doi":"10.1056/NEJMoa1914347"},{"title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","journal":"NEJM","year":2013,"doi":"10.1056/NEJMoa1306220"}]},"route":"/people/michael-wang/","neighbours":{"cancer":[{"id":"mantle-cell-lymphoma","kind":"cancer","name":"Mantle cell lymphoma","route":"/cancers/mantle-cell-lymphoma/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"bcl2","kind":"target","name":"BCL-2","route":"/targets/bcl2/"},{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"}],"drug":[{"id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/"}],"institution":[{"id":"md-anderson","kind":"institution","name":"MD Anderson Cancer Center","route":"/institutions/md-anderson/"}],"paper":[{"id":"paper-echo-acalabrutinib-bendamustine-rituximab-mantle-cell-jco-2025","kind":"paper","name":"Acalabrutinib plus bendamustine-rituximab in untreated mantle cell lymphoma","route":"/key-papers/paper-echo-acalabrutinib-bendamustine-rituximab-mantle-cell-jco-2025/"},{"id":"paper-shine-ibrutinib-bendamustine-rituximab-mantle-cell-nejm-2022","kind":"paper","name":"Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma","route":"/key-papers/paper-shine-ibrutinib-bendamustine-rituximab-mantle-cell-nejm-2022/"},{"id":"paper-zuma-2-brexu-cel-mantle-cell-nejm-2020","kind":"paper","name":"ZUMA-2: brexu-cel CAR-T for mantle cell lymphoma that has failed BTK inhibitors","route":"/key-papers/paper-zuma-2-brexu-cel-mantle-cell-nejm-2020/"}],"trial":[{"id":"shine","kind":"trial","name":"SHINE","route":"/trials/shine/"},{"id":"zuma-2","kind":"trial","name":"ZUMA-2","route":"/trials/zuma-2/"}],"roadmap":[{"id":"lymphoma-roadmap","kind":"roadmap","name":"Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting","route":"/roadmaps/lymphoma-roadmap/"}]}}